University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Thendor Therapeutics

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

Respiratory

Therapeutic Indications

Pulmonary fibrosisUrological fibrosisSystemic fibrotic disease

Founders

Carol Feghali-BostwickSteven KingPaul Lytle

Website

https://www.thendortx.com

Thendor Therapeutics is an early-stage company developing peptide-based medicines intended to halt or reverse fibrosis and restore healthy tissue function across a range of fibrotic diseases. [1]

Its areas of focus include pulmonary fibrosis, urological fibrosis through its subsidiary Thenduro, systemic fibrotic diseases driven by shared biological pathways, and exposure-induced fibrosis. The company was co-founded by fibrosis researcher Carol Feghali-Bostwick, who serves as acting chief scientific officer, together with CEO Steven King and CFO Paul Lytle. [2]

Discover More with AI